Protocol Ledger

NCT05001880 · Phase II · RECRUITING

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Interventional Phase II clinical trial protocol NCT05001880 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-22 Enrollment: 66 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05001880
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)66 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05001880
Protocol FieldVerified Registry Value
NCT IdentifierNCT05001880
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment66 participants (ESTIMATED)
Registered Start Date2022-03-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05001880
Hospital Research SiteLocationSite Profile
Mayo Clinic ArizonaPhoenix, AZOpen Hospital Dossier ->
University of Chicago MedicineChicago, ILOpen Hospital Dossier ->
Carle at The RiverfrontDanville, ILOpen Hospital Dossier ->
Carle Physician Group-EffinghamEffingham, ILOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI